SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Careers
Contact Us
Expanded Access Policy
Diabetes
Products
Manufacturing
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Financial Calendar
Skip Navigation Links
Home
»
Investors
»
Press Releases
Diamyd Medical’s financial year comprises 1 September – 31 August.
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Data pager
Data pager
1
2
Show:
PageSizeComboBox
select
10
20
50
100
150
2 pages
Press Releases
Data pager
Data pager
1
2
Show:
PageSizeComboBox
select
10
20
50
100
150
2 pages
5/16/2024
Diamyd Medical updates on the registrational Phase 3 trial; upcoming interim analysis and enrollment
4/18/2024
Diamyd Medical announces final outcome in the company’s rights issue
4/16/2024
Diamyd Medical announces preliminary outcome in the company’s rights issue
4/12/2024
Recruitment milestone reached in Diamyd
®
Phase 3 trial
4/11/2024
Diamyd Medical led ASSET innovation partnership organizes a workshop on the future treatment of Type 1 Diabetes
4/5/2024
Diamyd Medical's main Shareholders announce their subscription commitments in the ongoing rights issue
3/28/2024
Diamyd Medical publishes prospectus with regards to the rights issue
3/27/2024
Quarterly Report II 23/24
3/18/2024
The Board of Directors in Diamyd Medical have resolved on a rights issue of approximately SEK 114 million
2/29/2024
Diamyd Medical to present new genetic data at the ASIT summit in Boston, MA
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
|
Expanded Access Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research